undamentalytics Newsletter
Sign in

Avalo Therapeutics, Inc. income statement

In fiscal 2025, Avalo Therapeutics, Inc. reported revenue of $59,000, down 86.6% on the year before, operating income of −$72.9m (a -123601.7% margin) and net income of −$78.3m, or −$5.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue0128777518200
Cost of revenue——13−10131——
Gross profit——274764151——
Research and development7104612326031142450
Selling, general and administrative———————2110——
Selling and marketing0011123————
General and administrative47811101725——1723
Operating income−11−1614−35−16−73−82−37−27−69−73
Income before tax———————−42−32−35−78
Income tax002−00−3−00000
Net income−10−1612−40−16−64−84−42−32−35−78
Diluted EPS−$1130.40−$1.87$100.80−$1.20———−$1063.00−$113.58−$20.91−$5.84
Diluted shares (average)9m———————278m7m13m
EBITDA−11−1614−31−12−71−80−37−27−68−73

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AVTX vs CRDFAVTX vs CRVOAVTX vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Avalo Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Avalo Therapeutics, Inc.